Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED東瑞製葯(控股)有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2348) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017 FINANCIAL HIGHLIGHTSUnaudited | For the six months ended 30 June | ||
2017 | 2016 | Change | |
Revenue (RMB'000) | 491,056 | 418,449 | 17.4% |
Gross Profit (RMB'000) | 340,832 | 255,703 | 33.3% |
Gross Profit Margin | 69.4% | 61.1% | +8.3 percentage points |
Profit before tax (RMB'000) | 186,309 | 165,077 | 12.9% |
Profit for the period attributable to | |||
owners of the parent (RMB'000) | 148,968 | 131,480 | 13.3% |
Net Profit Margin | 30.3% | 31.4% | -1.1 percentage points |
Earnings per share - basic (RMB) | 0.1859 | 0.1638 | 13.5% |
Interim dividend per share (HK$) | 0.03 | 0.03 | 0.0% |
The board (the "Board") of directors (the "Directors") of Dawnrays Pharmaceutical (Holdings) Limited (the "Company") is pleased to announce the unaudited consolidated interim results of the Company and its subsidiaries (collectively, the "Group") for the six months ended 30 June 2017 (the "period"). These interim results have been reviewed by the audit committee of the Company.
INTERIM DIVIDENDThe Board has resolved to declare an interim dividend of HK$0.03 per share for the year ending 31 December 2017, approximately amounting to a total sum of HK$23,805,000 (approximately equivalent to RMB20,373,000).
For the six months ended 30 June | |||
2017 | 2016 | ||
(Unaudited) | (Unaudited) | ||
Notes | RMB'000 | RMB'000 | |
Revenue | 3 | 491,056 | 418,449 |
Cost of sales | (150,224) | (162,746) | |
Gross profit | 340,832 | 255,703 | |
Other income and gains | 3 | 13,713 | 11,497 |
Selling and distribution expenses | (102,392) | (47,342) | |
Administrative expenses | (40,012) | (28,911) | |
Other expenses | (24,159) | (25,793) | |
Finance costs | 4 | (13) | (77) |
Share of profits and losses of: | |||
Associates | (1,660) | - | |
PROFIT BEFORE TAX | 5 | 186,309 | 165,077 |
Income tax expense | 6 | (37,341) | (33,597) |
PROFIT FOR THE PERIOD | 148,968 | 131,480 | |
Attributable to: | |||
Owners of the parent | 148,968 | 131,480 | |
EARNINGS PER SHARE ATTRIBUTABLE TO | |||
ORDINARY EQUITY HOLDERS OF THE PARENT | 8 | ||
- basic, for profit for the period | RMB0.1859 | RMB0.1638 | |
- diluted, for profit for the period | RMB0.1859 | RMB0.1636 |
For the six months ended 30 June | ||
2017 | 2016 | |
(Unaudited) | (Unaudited) | |
RMB'000 | RMB'000 | |
PROFIT FOR THE PERIOD | 148,968 | 131,480 |
Other comprehensive (loss)/income to be reclassified to profit or loss in | ||
subsequent periods: | ||
Exchange differences | (2,410) | 649 |
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, | ||
NET OF TAX | (2,410) | 649 |
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, | ||
NET OF TAX | 146,558 | 132,129 |
Attributable to: | ||
Owners of the parent | 146,558 | 132,129 |
NON-CURRENT ASSETS | Notes | 30 June 2017 (Unaudited) RMB'000 | 31 December 2016 (Audited) RMB'000 |
Property, plant and equipment | 544,976 | 566,321 | |
Land use rights | 39,650 | 40,175 | |
Construction in progress | 7,869 | 5,776 | |
Intangible assets | 25,205 | 24,909 | |
Investments in associates | 48,670 | - | |
Deferred tax assets | 6,625 | 6,729 | |
Total non-current assets | 672,995 | 643,910 | |
CURRENT ASSETS Inventories | 9 | 118,944 | 124,746 |
Trade and notes receivables | 10 | 265,239 | 225,660 |
Prepayments, deposits and other receivables | 380,626 | 220,958 | |
Equity investments at fair value | |||
through profit or loss | 8,154 | 7,794 | |
Cash and bank | 534,453 | 663,296 | |
Total current assets | 1,307,416 | 1,242,454 | |
CURRENT LIABILITIES Trade and notes payables | 11 | 93,227 | 87,938 |
Other payables and accruals | 110,996 | 98,104 | |
Interest-bearing bank loans | - | 9,104 | |
Income tax payable | 20,033 | 5,510 | |
Total current liabilities | 224,256 | 200,656 | |
Net current assets | 1,083,160 | 1,041,798 | |
Total assets less current liabilities | 1,756,155 | 1,685,708 | |
NON-CURRENT LIABILITIES Government grants | 2,248 | 2,248 | |
Deferred tax liabilities | 47,663 | 46,704 | |
Total non-current liabilities | 49,911 | 48,952 | |
Net assets | 1,706,244 | 1,636,756 |
Dawnrays Pharmaceutical (Holdings) Ltd. published this content on 22 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 August 2017 04:42:09 UTC.
Original documenthttp://en.dawnrays.com/UploadFiles/AnnmentFile/e_DAWNRAYS(e)_announcement 170822.pdf
Public permalinkhttp://www.publicnow.com/view/98476311CEA3CB1B6F77CB3CB74ED77F562B28D2